Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Ader (lopinavir/ritonavir), 2021
 
NCT04315948
RCTlopinavir/ritonavirCOVID 19 hospitalizedsome concern
-/- ongoing
    Nojomi, 2020
     
    IRCT20180725040596N2
    RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
    50/50 inconclusive
      RECOVERY, 2020
       
      NCT04381936
      RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
      1616/3424 inconclusive
      • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
      SOLIDARITY (lopi/rito), 2020
       
      NCT04315948
      RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
      1399/1372 inconclusive
      • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

      COVID-19 mild to moderate meta-analysis

      ELACOI (lopinavir/ritonavir), 2020
       
      NCT04252885
      RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
      21/7 inconclusive

        COVID-19 severe or critically meta-analysis

        Cao B, 2020
         
        ChiCTR2000029308
        RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
        99/100 suggested
        • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
        REMAP-CAP (lopinavir/ritonavir only), 2020
         
        NCT02735707
        RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
        268/377 safety concern
        • statistically significant 17 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
        1 study excluded by filtering options (0 RCT / 1 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).